Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Cole R. Clifford"'
Autor:
Cole R. Clifford, Richard G. Jung, Benjamin Hibbert, Aun Yeong Chong, Marie Lordkipanidzé, Jean-Francois Tanguay, Derek Y.F. So
Publikováno v:
Platelets, Vol 33, Iss 2, Pp 298-303 (2022)
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or “Dual Pathway” (DP), using aspirin and rivaroxaban
Externí odkaz:
https://doaj.org/article/063e52ed46b04ab1a20537e66304a4be
Autor:
Cole R. Clifford, HBSc, Michel Le May, MD, FRCPC, Alyssa Chow, Rene Boudreau, MD, Angel Y.N. Fu, MD, FRCPC, Quinton Barry, MD, Aun Yeong Chong, MBBS, MD, MRCP, Derek Y.F. So, MD, FRCPC, FACC
Publikováno v:
CJC Open, Vol 3, Iss 5, Pp 565-573 (2021)
Background: Management of ST-elevated myocardial infarction (STEMI) necessitates rapid reperfusion. Delays prolong myocardial ischemia and increase the risk of complications, including death. The COVID-19 pandemic may have affected management of STEM
Externí odkaz:
https://doaj.org/article/08ef8bb7f2d14c9b8f016d5d5d197d91
Autor:
Trevor Simard, Marino Labinaz, Christopher Glover, Derek So, Cole R Clifford, Aun-Yeong Chong, Alexander Dick, Alyssa Chow, Q. Barry, Rene Boudreau, Michael Froeschl, U. Tran, Benjamin Hibbert, A. Fu, Michel R. Le May, Juan J Russo
Publikováno v:
The American Journal of Cardiology. 161:19-25
The optimal length of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains debated. Current guidelines recommend individualized treatment with consideration of risk scores. We sought to evaluate the degree of agreem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5973048dc4626b1a9f6946b0fd79b4c
https://doi.org/10.1016/j.amjcard.2021.08.055
https://doi.org/10.1016/j.amjcard.2021.08.055
Autor:
Derek So, Nikita Malhotra, Nathan Orr, Cole R Clifford, Q. Barry, Sarah Visintini, Rene Boudreau, A. Fu
Publikováno v:
European Heart Journal - Cardiovascular Pharmacotherapy. 8:511-518
Aims The PRECISE-DAPT (Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy) score identifies patients at high risk of bleeding complications following percutaneous coronary intervention
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3daba4d691e73ff8f0aa225f0928a41d
https://doi.org/10.1093/ehjcvp/pvab080
https://doi.org/10.1093/ehjcvp/pvab080
Autor:
Derek So, Q. Barry, Alexander Dick, Juan J Russo, Trevor Simard, Michael Froeschl, Christopher Glover, Marino Labinaz, Cole R Clifford, Benjamin Hibbert, Alyssa Chow, Angel Fu, Rene Boudreau, Michel R. Le May, Aun-Yeong Chong
Publikováno v:
CJC Open, Vol 3, Iss 9, Pp 1091-1099 (2021)
CJC Open
CJC Open
Background: De-escalation from potent platelet P2Y12 inhibitors to clopidogrel is common. Despite having a clinical rationale, non-bleeding-related de-escalation when a lateral change between potent agents is an option may put patients at increased i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bd868633a0196d4a68bb56f83e9ab5d
https://doi.org/10.1016/j.cjco.2021.04.010
https://doi.org/10.1016/j.cjco.2021.04.010
Autor:
Cole R Clifford, Jean-François Tanguay, Benjamin Hibbert, Marie Lordkipanidzé, Aun-Yeong Chong, Richard G. Jung, Derek So
Publikováno v:
Platelets. 33(2)
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or "Dual Pathway" (DP), using aspirin and rivaroxaban. No
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39a0ef54ae019ce7c54621583cbf459b
https://pubmed.ncbi.nlm.nih.gov/33856269
https://pubmed.ncbi.nlm.nih.gov/33856269
Autor:
Cole R Clifford, Richard G. Jung, Stephanie Skanes, Pietro Di Santo, Graeme Prosperi-Porta, Trevor Simard, Annie Hung, F. Daniel Ramirez, Sarah Visintini, Simon Parlow, Benjamin Hibbert
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
The COVID-19 pandemic began in early 2020 with major health consequences. While a need to disseminate information to the medical community and general public was paramount, concerns have been raised regarding the scientific rigor in published reports
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942c93c277cbcde39ce049390596c380
Autor:
Richard G. Jung, Simon Parlow, Sarah Visintini, Benjamin Hibbert, F. Daniel Ramirez, Cole R Clifford, Annie Hung, Graeme Prosperi-Porta, Stephanie Skanes, Pietro Di Santo, Trevor Simard
ObjectiveTo systematically evaluate the quality of reporting of currently available COVID-19 studies compared to historical controls.DesignA systematic review and case-control analysisData sourcesMEDLINE, Embase, and Cochrane Central Register of Cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5320675ee3218f108b884acea15a825c
https://doi.org/10.1101/2020.07.02.20145102
https://doi.org/10.1101/2020.07.02.20145102
Publikováno v:
Journal of the American College of Cardiology. 75:1193
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d9e481bf09ad2d868c6213218a1235a
https://doi.org/10.1016/s0735-1097(20)31820-9
https://doi.org/10.1016/s0735-1097(20)31820-9